AbbVie Inc. — Form 8-K
Filed September 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
AbbVie completed acquisition of Apogee Therapeutics for $135.11/share in cash, totaling ~$10.9B equity value. Apogee's lead asset zumilokibart (IL-13 targeted monoclonal antibody) showed Phase 2 efficacy in atopic dermatitis with ~67% achieving significant skin clearance at 16 weeks; pipeline includes APG273 combination therapy for asthma. Acquisition will dilute 2026 EPS by $0.14/share (partial year) and ~$0.46/share in 2027, with accretion beginning 2032; AbbVie reaffirmed full-year 2026 EPS guidance of $13.87–$14.07.
Why this rating
~3.4% of market cap; immuno pipeline bolt-on; near-term dilution; accretion delayed to 2032; routine M&A for large pharma.
See more from September 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.